RT Journal Article
T1 PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
A1 Rubio-Viqueira, Belen
A1 Tarruella, Margarita Majem
A1 Lazaro, Martin
A1 Estevez, Sergio Vazquez
A1 Cordoba-Ortega, Juan Felipe
A1 Maiques, Inmaculada Maestu
A1 Gonzalez, Jorge Garcia
A1 Cordellat, Ana Blasco
A1 Valdivia-Bautista, Javier
A1 Arenas, Carmen Gonzalez
A1 Sanchez Torres, Jose Miguel
K1 advanced
K1 first-line treatment
K1 immunotherapy
K1 metastatic
K1 NSCLC
K1 PD-L1 expression
K1 Open-label
K1 Pembrolizumab
K1 Chemotherapy
K1 Multicenter
K1 Therapy
K1 Phase-3
AB Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. Results: Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1. Conclusion: PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.
PB Future medicine ltd
SN 1758-1966
YR 2021
FD 2021-11-26
LK https://hdl.handle.net/10668/26310
UL https://hdl.handle.net/10668/26310
LA en
DS RISalud
RD Apr 10, 2025